Navigation Links
Metformin's Anti-Cancer Properties Clarified in an Obesity Cell Model of Pancreatic Cancer
Date:7/22/2013

Los Angeles, California (PRWEB) July 22, 2013

SiDMAP, LLC, a leading provider of targeted 13C tracer fate association studies and biomarker development services, announces the publication of findings that metformin inhibits carbon flux towards new fatty acid synthesis in the presence of cholesterol, a known diseases factor in obesity and diabetes, to facilitate pancreatic cancer growth. The integrated nutritional and 13C Isotopolome-Wide Association Study with cholesterol administration to pancreatic cancer cell lines, is published in the official journal of the Metabolomics Society in collaboration with scientists at the University of Arizona, Department of Nutritional Sciences and the University of Arizona Cancer Center.

SiDMAP scientists provided the metabolic analysis for the study using pancreatic cancer cells expressing K-ras differently, which is a common mutation in pancreatic cancer. They integrated positional 13C labeling in multiple metabolic products in diverse sampling sites from a single 13C labeled glucose tracer. It is known that stable expression of K-ras induces a pancreatic cancer metabolic phenotype that competes for new acetate, formed from glucose, in the cholesterol and fatty acid producing pathways. “Cholesterol administration diverts new acetate towards fatty acid synthesis, which provides the contextual factor for metformin to inhibit new fatty acid synthesis, cell membrane turnover and potentially cell growth,” said Dr. Laszlo G. Boros, Chief Scientist at SiDMAP.

“The study may explain the mechanism of how elevated circulating cholesterol, which is an important disease modifying factor in the diabetic pancreatic cancer patient, alters cellular metabolism in a way that metformin’s known fatty acid synthase inhibiting effect becomes a cell growth limiting factor,” said Dr. Emmanuelle J. Meuillet, the study’s lead investigator.

The work is published as a Springer Open Access article, online first, in the journal Metabolomics and is titled, “Contextual inhibition of fatty acid synthesis by metformin involves glucose-derived acetyl-CoA and cholesterol in pancreatic tumor cells.” http://link.springer.com/article/10.1007%2Fs11306-013-0555-4

The study was supported by the Hirshberg Foundation for Pancreatic Cancer Research (http://www.pancreatic.org). “It is a key goal of the Foundation to bring lead scientists together to shed light on well-known, yet unexplained disease controlling mechanism of national research interest in obesity, diabetes and pancreatic cancer. This research is significant because it is in line with the National Cancer Institute’s quest to find bold new approaches to answer the perplexing scientific question of why the mechanism of a drug like metformin, which is generally used for other indications, protects against cancer incidence and mortality,“ said Agi Hirshberg, President of the Foundation.

About SiDMAP
SiDMAP provides flux-based, metabolic profiling services to pharmaceutical, biotech and research organizations seeking to enhance their drug development processes, and develop further insights into a drug’s mechanism of action and disease states. SiDMAP’s unique tracer technology measures metabolic pathway flux to gain unique insights into cell function. A SiDMAP assay provides clients with an accurate, dynamic metabolic analysis of a compound’s biological impact in both in vitro and in vivo systems, before a company spends millions more on development and clinical trials. SiDMAP is headquartered in Los Angeles, California.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10947481.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. New understanding of why anti-cancer therapy stops working at a specific stage
2. Anti-cancer drug viewed as possible Alzheimers treatment doesnt work in UF study
3. Overcoming resistance to anti-cancer drugs by targeting cell powerhouses
4. Progress after recent breakthrough which opened new chapter in anti-cancer cell therapies
5. Development of the first way to make large amounts of promising anti-cancer substance
6. First trial in humans of minicells: A completely new way of delivering anti-cancer drugs
7. Specialized MRI scans assess value of anti-cancer chemotherapy long before tumors shown to shrink
8. 1960s-era anti-cancer drug points to treatments for Lou Gehrigs disease
9. Moffitt Cancer Center researchers develop and test new anti-cancer vaccine
10. Patent Issued for Apparel and Textile Fabric with Antimicrobial Properties
11. New studies explore mangos potential health-affirming properties
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... TX (PRWEB) , ... June 24, 2016 , ... People ... part in Genome magazine’s Code Talker Award, an essay contest in which patients and ... an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) ...
(Date:6/24/2016)... York, NY (PRWEB) , ... June 24, 2016 ... ... publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as a ... that “the most beautiful women in the world, and the most handsome men, ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
(Date:6/24/2016)... ... , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event ... that have been wounded in battle and their families. Venture Construction Group is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... upcoming 2016 Miss Arizona pageant as its official Medspa Sponsor. Dr. Josh Olson, ... and Chandler, Arizona. , Dr. Olson says the decision to support the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... ANDOVER, Mass. and SAN CLEMENTE, Calif. ... California -based mobile pulmonary function testing company, is now ... portable PFT devices developed by ndd Medical Technologies , Inc. ... PFT testing done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ... CA , can get any needed testing done in the ...
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
Breaking Medicine Technology: